Bristol Myers Squibb Co. has presented macrocyclic peptides acting as programmed cell death 1 (PD-1)/PD-1 ligand 1 (PD-L1) interaction inhibitors reported to be useful for the treatment of cancer and infections.
Genentech Inc. has discovered sulfonimidamide compounds acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of cancer, autoimmune disease and cardiovascular, dermatological, respiratory, neurological, gastrointestinal and inflammatory disorders, among others.
Recurium IP Holdings LLC has patented antibody-drug conjugates (ADCs) comprising antibodies targeting inactive tyrosine-protein kinase transmembrane receptor ROR1 covalently bound to exatecan through a linker reported to be useful for the treatment of cancer.
Shanghai Qilu Pharmaceutical Research and Development Centre Ltd. has presented protein arginine N-methyltransferase 5 (PRMT5) inhibitors reported to be useful for the treatment of cancer.
Jiangsu Hengrui Medicine Co. Ltd., Shanghai Hengrui Pharmaceutical Co. Ltd., Shanghai Senhui Pharmaceutical Co. Ltd. and Shanghai Shengdi Pharmaceutical Co. Ltd. have identified antibody-drug conjugates (ADCs) comprising HER2-targeting antibody or antigen-binding fragments linked to eribulin derivatives through a cleavable linker reported to be useful for the treatment of cancer.
Tuojie Biotech (Shanghai) Co. Ltd. has described lysophosphatidic acid receptor 1 (LPAR1) antagonists reported to be useful for the treatment of metabolic diseases, cancer, liver diseases, respiratory, renal, neurological, cardiovascular and eye disorders, among others.
Micurx Pharmaceuticals Inc. has patented peptide-drug conjugates consisting of peptide targeting kidney cells covalently linked to an anti-inflammatory or immunomodulating or nephron-protective drug through a linker reported to be useful for the treatment of acute kidney injury, chronic kidney disease, chronic glomerulonephritis, diabetic nephropathy and systemic lupus erythematosus, among others.
RSS